Comparison of direct medical cost between ramipril and candesartan in hospitalized acute decompensated heart failure at West Nusa Tenggara Regional Hospital

By Nurul Qiyaam
Comparison of direct medical cost between ramipril and candesartan in hospitalized acute decompensated heart failure at West Nusa Tenggara Regional Hospital

Nurul Qyam, Baqi Leny Nopitasari, Cyntia Rahmawati, Biaq Nurbayti, Emasiska Ajeng Pratiwi

ABSTRACT

Introduction: Pharmacoeconomics is the field of study regarding cost analysis associated with the use of drugs in health care. The purpose of pharmacoeconomics is to compare a different drug used in the treatment of the same condition or can be the opposite, i.e. comparing different treatments in different circumstances. The purpose of this study is to determine and compare the average efficiency of direct medical costs between ramipril and candesartan combination drug in hospitalized heart failure patients with a payer perspective at the West Nusa Tenggara Regional General Hospital, Mataram, Indonesia.

Method: This study is part of an economic evaluation of direct medical cost analysis research in hospitalized heart failure patients with a payer perspective. Study design using a retrospective approach involving 45 patients with heart failure who meet the study inclusion criteria and exclusion criteria. Independent t-test was used to compare the direct medical cost between ramipril and candesartan.

Results: The average gross total cost of using ramipril combination was Rp. 4,197,011 while the average total cost of using candesartan combination was Rp. 3,099,088. These results indicate there are savings in the average total cost of treatment for heart failure using candesartan that is Rp. 1,097,923. Candesartan combination provides the lowest value and is a more efficient choice compared to ramipril combination. Meanwhile, after t-test comparison reveal no significant different average direct medical costs in patients using the ramipril combination compared with the candesartan combination (p > 0.05).

Conclusion: The results of this study indicate that there is no significant difference between the average direct medical costs in patients using ramipril compared with candesartan combination.

Keywords: heart failure, ramipril, candesartan, cost analysis, direct medical costs.

Cite This Article: Qyam, N., Nopitasari, B.L., Rahmawati, C., Nurbayti, B., Pratiwi, E.A. 2020. Comparison of direct medical cost between ramipril and candesartan in hospitalized acute decompensated heart failure at West Nusa Tenggara Regional Hospital. *Bali Medical Journal* 9(2): 423-429. DOI: 10.15562/bmj.v9i2.1871

INTRODUCTION

The heart is the most important organ in circulation. The heart works to pump blood throughout the body to meet the body’s metabolic needs at all times, both at rest and work. Most sufferers live after having a heart attack but then suffer heart failure.12 Heart failure is a clinical syndrome caused by structural and/or functional abnormalities. Heart failure is a growing problem throughout the world, with more than 20 million people affected by heart failure.3,4 In developed countries the prevalence of heart failure in the adult age group reaches 2% of the population.5 The prevalence of heart failure increases with age and affects 6-10% of people over 65 years.6-8

The World Health Organization (WHO) notes that 17.9 million people worldwide die from cardiovascular disorders with a percentage of 31% of deaths worldwide. More than 75% of cardiovascular sufferers occur in low and middle-income countries, and 80% of cardiovascular deaths are caused by heart attacks and strokes.9 In Indonesia, as many as 13,395 people with heart failure undergoing hospitalization, while as many as 16,431 people were undergoing outpatient treatment in all hospitals around Indonesia. In 2018 the results of Basic Health Research showed that the incidence of heart failure increased by 1.5% in Indonesia. While in the West Nusa Tenggara region the prevalence is 0.8%.10

The additional cost-effectiveness ratio to expand the coverage of all heart failure patients is $ 9,700 per life-year gained obtained in the base case. An analysis of the worst case of heart failure assuming simultaneous conservative results in an additional cost-effective ratio of $ 110,000 per life-year gained. In a probabilistic sensitivity analysis, 99.74% of the possible additional ratios of cost-effective heart failure that were < 50,000 per life-year gained.11 The cost of treatment is a very important issue for developing countries like Indonesia. One that
affects the amount of the cost of handling heart failure is the type of drug used. Therefore in the treatment of heart failure a rational and comprehensive treatment is needed to achieve optimal medical service.\textsuperscript{11}–\textsuperscript{12}

Pharmacoeconomics is the field of study regarding costs analysis associated with the use of drugs in health care. The purpose of pharmacoeconomics is to compare a different drug used in the treatment with the same condition or can be the opposite, ie comparing different treatments in different conditions.\textsuperscript{13} The results of the pharmacoeconomics can be used as a reference or assist policymakers in determining choices for available treatment alternatives so that health services become more efficient and economical. The study aims to determine and compare the average efficiency of direct medical costs between ramipril and candesartan combination drug in hospitalized heart failure patients with a payer perspective at the West Nusa Tenggara Regional General Hospital, Mataram, Indonesia.

**METHOD**

This study is part of a hospital economic evaluation of direct medical cost analysis in acute decompensated heart failure hospitalization. Study design using a retrospective approach with a payer’s perspective.\textsuperscript{14} The inclusion criteria in this study were patients with main diagnoses of acute decompensated heart failure who were hospitalized in West Nusa Tenggara Regional Hospital who were seeking treatment in the period 2018.

The type of data in this study is secondary data from hospital information system (SIRS), where the data obtained was the primary diagnosed heart failure patient data that met the patient criteria in the study which included age, sex, concomitant diseases and use of combination of ramipril (furosemide 40 mg, spironolactone 25 mg, bisoprolol 5 mg, ramipril 5 mg) or using a combination of candesartan (furosemide 40 mg, spironolactone 25 mg, bisoprolol 5 mg, candesartan 16 mg) West Nusa Tenggara Regional Hospital 2018. The criteria used in assessing costs is the comparison between heart failure patients using the combination of ramipril compared to candesartan combination. A total of 240 patients diagnosed with heart failure who received treatment at West Nusa Tenggara Regional Hospital in 2018, 45 samples were obtained that met the inclusion criteria. 33 patients were using the Ramipril combination and 12 patients using the candesartan combination.

Statistical analysis in this study using SPSS version 21.0 (IBM Corporation, Armonk, NY, USA). Independent t-tests was used to compare direct medical cost between ramipril and candesartan combination. All value considered significant if p<0.05.

**RESULT**

**Characteristics of the study**

Based on the results of this study indicate that inpatient heart failure patients in RSUDP NTB who received therapy with the combination of ramipril were 17 people (51.52%) were male and 16 people (48.48%) were female. While those who received candesartan therapy were 8 people (66.67%) who were male and 4 people (33.33%) were female. These results indicate that more heart failure patients are male than female. Meanwhile, in age characteristics shows, 18-65 years of age most diagnosed with heart failure by 81.82% and age ≥ 65 years by 18.18%. While the characteristics of age at Candesartan are age 35-65 years as much as 58.34% and age ≥ 65 years as much as 41.66%. Based on characteristics of concomitant diseases in the ramipril combination group of 90.9% had concomitant diseases and as many as 9.1% who did not have concomitant diseases. Whereas in the candesartan combination group all patients had concomitant disease (100%). In both groups it was seen that the majority of heart failure patients in the were mostly accompanied by concomitant diseases. Life status characteristics shows in the ramipril group patients mostly died (57.58%) compared to the number of living patients by 42.42%. Whereas in the candesartan group it was known that heart failure patients who died by 66.67% and patients living by 33.33% (Table 1).

**Direct Medical Cost**

The description of medical expenses at the hospital can be used as input in determining the planning and control of hospital services. Costs that will be calculated in this study are direct medical costs including ramipril and candesartan drugs, other drugs, medical equipment costs, doctor’s fees, nurse fees, laboratory fees, accommodation costs.

Based on Table 2, the average cost of drugs for heart failure patients using a combination of ramipril and candesartan combination has a different amount of costs. The difference in costs in each class is influenced by differences in length of stay, the number of drugs used and comorbidities besides heart failure and the types of drugs consumed so that it affects the costs that must be paid by the payer. The payer in this case is the Indonesian National Health Insurance Administering Agency (BPJS).
### Table 1 Clinical characteristics

| Characteristics | Drugs combination | Total (n=45) | Percentage (%) |
|-----------------|-------------------|-------------|----------------|
|                 | Ramipril          | Candesartan | Ramipril n=33  | Candesartan n=12 | Ramipril | Candesartan |
| Sex             | Male              | Male        | 17             | 8              | 51.51%   | 66.66%   |
|                 | Female            | Perempuan   | 16             | 4              | 48.48%   | 33.33%   |
| Age             | 18-65 years       | 36-65 tahun| 27             | 7              | 81.81%   | 58.33%   |
|                 | ≥ 65 years        | ≥ 65 tahun  | 6              | 5              | 18.18%   | 41.66%   |
| Comorbidities   | With comorbidities| With comorbidities| 3           | 0              | 90.9%    | 100%     |
|                 | Without comorbidities| Without comorbidities| 30       | 12             | 9.1%     | 0%       |
| Status          | Alive             | Alive       | 14             | 4              | 42.42%   | 33.33%   |
|                 | Death             | Death       | 19             | 8              | 57.57%   | 66.66%   |

### Table 2 Medication cost between ramipril and candesartan combination

| Medication | Inpatient class | Number of patient | Item total cost (IDR) | Average medication cost (IDR) |
|------------|-----------------|-------------------|------------------------|-------------------------------|
| Ramipril   | VIP             | 5                 | 71,773                 | 14,355                        |
|            | 1               | 2                 | 44,213                 | 22,106                        |
|            | 2               | 7                 | 77,017                 | 11,002                        |
|            | 3               | 19                | 242,055                | 12,739                        |
| Candesartan| VIP             | 3                 | 74,948                 | 24,983                        |
|            | 1               | 1                 | 26,964                 | 26,964                        |
|            | 2               | 2                 | 24,771                 | 12,385                        |
|            | 3               | 6                 | 123,401                | 20,566                        |

### Table 3 Others medication cost comparison between ramipril and candesartan combination

| Medication | Inpatient class | Number of patient | Item total cost (IDR) | Average medication cost (IDR) |
|------------|-----------------|-------------------|------------------------|-------------------------------|
| Ramipril   | VIP             | 5                 | 1,918,688              | 383,738                       |
|            | 1               | 2                 | 5,497,997              | 2,748,998                     |
|            | 2               | 7                 | 766,951                | 110,993                       |
|            | 3               | 19                | 19,897,806             | 1,047,252                     |
| Candesartan| VIP             | 3                 | 1,849,651              | 616,550                       |
|            | 1               | 1                 | 318,754                | 318,754                       |
|            | 2               | 2                 | 148,499                | 74,249                        |
|            | 3               | 6                 | 1,991,553              | 331,925                       |

### Table 4 Medical equipment cost comparison between ramipril and candesartan combination

| Medication | Inpatient class | Number of patient | Item total cost (IDR) | Average equipment cost (IDR) |
|------------|-----------------|-------------------|------------------------|-------------------------------|
| Ramipril   | VIP             | 5                 | 573,504                | 114,719                       |
|            | 1               | 2                 | 643,676                | 321,838                       |
|            | 2               | 7                 | 620,930                | 88,704                        |
|            | 3               | 19                | 26,330,366             | 1,385,808                     |
| Candesartan| VIP             | 3                 | 845,265                | 281,755                       |
|            | 1               | 1                 | 219,409                | 219,409                       |
|            | 2               | 2                 | 54,062                 | 27,031                        |
|            | 3               | 6                 | 1,140,748              | 190,124                       |
**Tabel 5** Average doctor visit and hospitalization cost comparison between ramipril and candesartan combination

| Medication | Inpatient class | Number of patient | Item total cost (IDR) | Average fee cost (IDR) |
|------------|----------------|------------------|-----------------------|------------------------|
| **Doctor visit fee** | | | | |
| Ramipril | VIP | 5 | 2,625,000 | 525,000 |
| | 1 | 2 | 1,020,000 | 510,000 |
| | 2 | 7 | 1,000,000 | 142,857 |
| | 3 | 19 | 3,620,000 | 190,526 |
| Candesartan | VIP | 3 | 3,875,000 | 1,291,667 |
| | 1 | 1 | 180,000 | 180,000 |
| | 2 | 2 | 220,000 | 110,000 |
| | 3 | 6 | 1,200,000 | 200,000 |
| **Hospitalization cost** | | | | |
| Ramipril | VIP | 5 | 5,695,350 | 1,139,070 |
| | 1 | 2 | 5,898,600 | 2,949,300 |
| | 2 | 7 | 3,579,200 | 511,314 |
| | 3 | 19 | 17,974,973 | 946,051 |
| Candesartan | VIP | 3 | 3,647,133 | 1,215,711 |
| | 1 | 1 | 394,600 | 394,600 |
| | 2 | 2 | 741,223 | 370,616 |
| | 3 | 6 | 5,030,075 | 838,345 |

**Tabel 6** Average laboratory cost comparison between ramipril and candesartan combination

| Medication | Inpatient class | Number of patient | Item total cost (IDR) | Average cost (IDR) |
|------------|----------------|------------------|-----------------------|-------------------|
| **Laboratory cost** | | | | |
| Kombinasi Ramipril | VIP | 5 | 4,707,050 | 941,410 |
| | 1 | 2 | 1,645,000 | 822,500 |
| | 2 | 7 | 2,389,783 | 341,397 |
| | 3 | 19 | 8,306,340 | 422,565 |
| Kombinasi Candesartan | VIP | 3 | 1,749,000 | 583,000 |
| | 1 | 1 | 205,000 | 205,000 |
| | 2 | 2 | 389,000 | 194,500 |
| | 3 | 6 | 1,690,000 | 281,666 |
| **Accommodation cost** | | | | |
| Ramipril | VIP | 5 | 6,500,000 | 1,300,000 |
| | 1 | 2 | 2,550,000 | 1,275,000 |
| | 2 | 7 | 1,875,000 | 267,857 |
| | 3 | 19 | 6,200,000 | 331,578 |
| Candesartan | VIP | 3 | 8,150,000 | 2,716,667 |
| | 1 | 1 | 300,000 | 300,000 |
| | 2 | 2 | 450,000 | 225,000 |
| | 3 | 6 | 1,450,000 | 241,666 |

Based on Table 3, the average cost of other drugs for heart failure patients using the combination of ramipril and candesartan combination has a different amount of costs. Costs for drugs other than heart failure include medications used to treat comorbidities in addition to heart failure. Common comorbidities in heart failure patients are hypertension, diabetes mellitus, and myocardial infarction.
Non-cardiovascular drugs used include ranitidine, lansoprazole, metformin, simvastatin, clopidogrel, and ceftriaxone.

Based on Table 4, the average cost of medical devices for heart failure patients using a combination of ramipril and candesartan has a different amount of costs. The difference in the cost of medical equipment in each class is influenced by differences in length of stay and the number of equipment used, so that it affects the cost that must be paid by the payer.

Based on Table 5, the average cost of doctors fee and hospitalization cost using a combination of ramipril and candesartan combination has a different amount of costs. The difference in costs in each class is influenced by differences in length of stay, number of drugs, medical equipment and service (oxygen installation, blood sampling, adult infusion set), and comorbidities in addition to heart failure and types of drugs used, so that influenced the costs to be paid by the National Health Insurance (BPJS).

Based on Table 6, there is a difference in the cost of the laboratory and accommodation between ramipril and candesartan combination. Laboratory examination costs are preoperative and postoperative preparations, for patients who will undergo surgery required an individual examination based on the patient’s condition. Differences in patient conditions cause different types, amounts and laboratory costs that must be incurred during treatment. Meanwhile, difference in accommodation cost due class difference that affects the costs borne by patients. The cost for each class is different because the facilities of each room class are different. The cost of the VIP class is greater because the number of beds in the room has complete facilities compared to other treatment classes.

Based on Table 7, the average cost of emergency room much higher in the ramipril combination Rp. 241,667 compared to the candesartan combination of Rp. 142,857. This is because the actual number of patients who get the ramipril combination more than patients who get the candesartan combination. Meanwhile, the average cost of the intensive cardiac care unit on the ramipril combination is Rp. 700,000, while for candesartan combinations Rp. 0. This happens due to samples in studies that received candesartan combination therapy none were treated in the intensive ward.

**Direct medical cost analysis**
Based on Table 8, the average direct medical costs of patients using the Ramipril combination amounted to IDR 4,197,011 while the average direct medical

| Medication | Item total cost (IDR) | Average cost (IDR) |
|------------|-----------------------|--------------------|
| Kombinasi Ramipril | 2,900,000 | 241,667 |
| Kombinasi Candesartan | 1,000,000 | 142,857 |
| Intensive cardiac care unit cost |
| Kombinasi Ramipril | 3,500,000 | 700,000 |
| Kombinasi Candesartan | 0 | 0 |

The difference in the direct medical cost between ramipril and candesartan is statistically significant (p = 0.570). The total mean difference of direct medical cost is IDR 1,097,923.

| Medication | Inpatient class | Number of patient | Total direct medical cost (IDR) | Average direct medical cost (IDR) |
|------------|----------------|-------------------|---------------------------------|---------------------------------|
| Ramipril   | VIP            | 5                 | 22,591,455                      | 4,518,291                       |
|            | 1              | 2                 | 19,049,486                      | 9,524,743                       |
|            | 2              | 7                 | 11,908,881                      | 1,701,269                       |
|            | 3              | 19                | 84,951,540                      | 4,471,134                       |
| Total      |                |                   | 138,501,362                     | 4,197,011                       |
| Candesartan| VIP            | 3                 | 20,290,997                      | 6,763,666                       |
|            | 1              | 1                 | 1,744,727                       | 1,744,727                       |
|            | 2              | 2                 | 2,027,555                       | 1,013,778                       |
|            | 3              | 6                 | 13,125,777                      | 2,187,630                       |
| Total      |                |                   | 37,189,956                      | 3,099,088                       |

Mean difference of direct medical cost IDR 1,097,923
research which states that the use of candesartan drugs is more efficient than the use of other medications for treatment in patients with heart failure.21

Another study conducted by Schadlich et al. Regarding cost effectiveness of ramipril in patients with heart failure in myocardial infarction in Germany, there is a variation in the value of ramipril that is 2500 to 8300 deutschmarks (DM) per life-year gained and ramipril shows a favourable cost incremental cost-effectiveness ratio in heart failure treatment compared to placebo.22

Another study conducted in Indonesia by Baroro et al. Regarding the cost-effectiveness of candesartan compared to the combination of candesartan amlodipine in patients with hypertension in the setting of an outpatient clinic, it shows that candesartan alone has a better cost-effectiveness of IDR 580,993 in one month of treatment.23

CONCLUSION

We concluded there was no significant difference between the average direct medical costs in patients using the ramipril combination compared with the candesartan combination. Economically the candesartan combination drug saves more costs (IDR 3,099,088) compared to the ramipril combination (IDR 4,197,011) with an average difference in cost of Rp. 1,097,923.

CONFLICT OF INTEREST

The authors declare there is no conflict of interest regarding publication of current study.

FUNDING

The current study doesn’t receive any specific grant from government or any private sectors.

ETHICAL STATEMENT

This study was conducted after obtaining ethical clearance from director of West Nusa Tenggara Regional Hospital, with ethical clearance reference number number 070/2037/RSUDP NTB.
Comparison of direct medical cost between ramipril and candesartan in hospitalized acute decompensated heart failure at West Nusa Tenggara Regional Hospital

Originality Report

20%

Similarity Index

Matched Source

1 balimedicaljournal.org
Internet

★balimedicaljournal.org
Internet

476 words — 14%

Exclude Quotes OFF
Exclude Bibliography OFF
Exclude Matches OFF

Link untuk mengecek plagiasi adalah https://app.ithenticate.com/en_us/dv/0425?o=63116370&lang=en_us